A new citrate-free formulation of ixekizumab, which is bioequivalent to the original version, has been linked to a substantial reduction in injection site pain, according to a recent study assessing patient satisfaction. This non-interventional, observational, web-based survey included adults with conditions such as psoriasis, psoriatic arthritis, or axial spondyloarthritis, who were part of the Taltz US Customer Support Program between August 2022 and March 2023. The survey aimed to evaluate patient satisfaction with their first injection experience of citrate-free ixekizumab, including their willingness to continue its use and recommendation, as well as their formulation preference.
The researcher’s findings, which included 451 patients in the analysis, revealed that a significantly higher percentage of patients expressed satisfaction with their first injection of citrate-free ixekizumab compared with the original formulation (83.9% vs 71.7%). Among those who switched from the original to the citrate-free ixekizumab, a notable 93.9% were definitely or mostly willing to continue its use, and 93.4% were likely to recommend it. This research underscores the citrate-free ixekizumab formulation’s preference and acceptance among most patients, both switchers and new users.
Reference: Chabra S, Birt J, Bolce R, et al. Satisfaction with the Injection Experience of a New, Citrate-Free Formulation of Ixekizumab. Adv Ther. Published online March 5, 2024. doi: 10.1007/s12325-024-02812-1.
Link: https://link.springer.com/article/10.1007/s12325-024-02812-1
